Francisca FERRER MARÍN

Alvarez-Larran A, Cuevas B, Velez P, Noya S, Caballero-Navarro G, Ferrer-Marin F, Carbonell S, Perez-Encinas M, Gomez-Casares MT, Perez-Lopez R, Magro E, Moreto A, Pastor-Galan I, Angona A, Mata-Vazquez MI, Guerrero-Fernandez L, Guerra JM, Carreno-Tarragona G, Fox L, Murillo I, Garcia-Gutierrez V, Mora E, Stuckey R, Arellano-Rodrigo E, Hernandez-Boluda JC, Pereira A. Application of IPSET-thrombosis in 1366 Patients Prospectively Followed From the Spanish Registry of Essential Thrombocythemia. Hemasphere. 2023 Jul 18;7(8):e936. doi: 10.1097/HS9.0000000000000936. eCollection 2023 Aug. PubMed PMID: 37476303; PubMed Central PMCID: PMC10356121.

AÑO: 2023; IF: 6.6

37476303

Hurtado-Navarro L, Cuenca-Zamora EJ, Zamora L, Bellosillo B, Such E, Soler-Espejo E, Martinez-Banaclocha H, Hernandez-Rivas JM, Marco-Ayala J, Martinez-Alarcon L, Linares-Latorre L, Garcia-Avila S, Amat-Martinez P, Gonzalez T, Arnan M, Pomares-Marin H, Carreno-Tarragona G, Chen-Liang TH, Herranz MT, Garcia-Palenciano C, Morales ML, Jerez A, Lozano ML, Teruel-Montoya R, Pelegrin P, Ferrer-Marin F. NLRP3 inflammasome activation and symptom burden in KRAS-mutated CMML patients is reverted by IL-1 blocking therapy. Cell Rep Med. 2023 Dec 19;4(12):101329. doi: 10.1016/j.xcrm.2023.101329. PubMed PMID: 38118408.

AÑO: 2023; IF: 14.3

38118408

Carreno-Tarragona G, Alvarez-Larran A, Harrison C, Martinez-Avila JC, Hernandez-Boluda JC, Ferrer-Marin F, Radia DH, Mora E, Francis S, Gonzalez-Martinez T, Goddard K, Perez-Encinas M, Narayanan S, Raya JM, Singh V, Gutierrez X, Toth P, Amat-Martinez P, Mcilwaine L, Alobaidi M, Mayani K, McGregor A, Stuckey R, Psaila B, Segura A, Alvares C, Davidson K, Osorio S, Cutting R, Sweeney CP, Rufian L, Moreno L, Cuenca I, Smith J, Morales ML, Gil-Manso R, Koutsavlis I, Wang L, Mead AJ, Rozman M, Martinez-Lopez J, Ayala R, Cross NCP. CNL and aCML should be considered as a single entity based on molecular profiles and outcomes. Blood Adv. 2023 May 9;7(9):1672-1681. doi: 10.1182/bloodadvances.2022008204. PubMed PMID: 36375042; PubMed Central PMCID: PMC10182308.

AÑO: 2023; IF: 7.5

36375042

Mosquera-Orgueira A, Perez-Encinas M, Hernandez-Sanchez A, Gonzalez-Martinez T, Arellano-Rodrigo E, Martinez-Elicegui J, Villaverde-Ramiro A, Raya JM, Ayala R, Ferrer-Marin F, Fox ML, Velez P, Mora E, Xicoy B, Mata-Vazquez MI, Garcia-Fortes M, Angona A, Cuevas B, Senin MA, Ramirez-Payer A, Ramirez MJ, Perez-Lopez R, Gonzalez de Villambrosia S, Martinez-Valverde C, Gomez-Casares MT, Garcia-Hernandez C, Gasior M, Bellosillo B, Steegmann JL, Alvarez-Larran A, Hernandez-Rivas JM, Hernandez-Boluda JC. Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis. Hemasphere. 2022 Dec 20;7(1):e818. doi: 10.1097/HS9.0000000000000818. eCollection 2023 Jan. PubMed PMID: 36570691; PubMed Central PMCID: PMC9771324.

AÑO: 2023; IF: 8.3

36570691

Morales ML, Ferrer-Marin F. Deepening Our Understanding of the Factors Affecting Landscape of Myeloproliferative Neoplasms: What Do We Know about Them? Cancers (Basel). 2023 Feb 20;15(4):1348. doi: 10.3390/cancers15041348. PubMed PMID: 36831689; PubMed Central PMCID: PMC9954305.

AÑO: 2023; IF: 6.575

36831689